US AI Drug Discovery Market Size, Share, Trends & Forecast

The US AI Drug Discovery Market is expanding rapidly as pharmaceutical companies, biotechnology firms, and research institutions increasingly adopt artificial intelligence to improve drug development. Market Research Future estimates that the market was valued at USD 211.57 million in 2024 and is projected to reach USD 2.49 billion by 2035, representing a CAGR of 25.15% from 2025 to 2035.

AI technologies can support target identification, lead optimization, drug repurposing, preclinical testing, and clinical research. By processing large volumes of biological and pharmaceutical data, AI systems can help researchers identify patterns and prioritize promising candidates.

The United States has a strong pharmaceutical and biotechnology ecosystem, providing favorable conditions for AI adoption. Increasing investment in computational technologies and research infrastructure is further strengthening the market.

Collaboration between technology companies, pharmaceutical manufacturers, biotechnology firms, and academic institutions is another important trend. Such partnerships can combine specialized AI capabilities with pharmaceutical expertise and proprietary datasets.

As investment in AI-enabled research continues to increase, the US market is positioned to remain an important center for technology-driven drug discovery.

Read More
Lukoon https://lukoon.com